Literature DB >> 25736181

Abnormal immune system development and function in schizophrenia helps reconcile diverse findings and suggests new treatment and prevention strategies.

Sherry Anders1, Dennis K Kinney2.   

Abstract

Extensive research implicates disturbed immune function and development in the etiology and pathology of schizophrenia. In addition to reviewing evidence for immunological factors in schizophrenia, this paper discusses how an emerging model of atypical immune function and development helps explain a wide variety of well-established - but puzzling - findings about schizophrenia. A number of theorists have presented hypotheses that early immune system programming, disrupted by pre- and perinatal adversity, often combines with abnormal brain development to produce schizophrenia. The present paper focuses on the hypothesis that disruption of early immune system development produces a latent immune vulnerability that manifests more fully after puberty, when changes in immune function and the thymus leave individuals more susceptible to infections and immune dysfunctions that contribute to schizophrenia. Complementing neurodevelopmental models, this hypothesis integrates findings on many contributing factors to schizophrenia, including prenatal adversity, genes, climate, migration, infections, and stress, among others. It helps explain, for example, why (a) schizophrenia onset is typically delayed until years after prenatal adversity, (b) individual risk factors alone often do not lead to schizophrenia, and (c) schizophrenia prevalence rates actually tend to be higher in economically advantaged countries. Here we discuss how the hypothesis explains 10 key findings, and suggests new, potentially highly cost-effective, strategies for treatment and prevention of schizophrenia. Moreover, while most human research linking immune factors to schizophrenia has been correlational, these strategies provide ethical ways to experimentally test in humans theories about immune function and schizophrenia. This article is part of a Special Issue entitled SI: Neuroimmunology in Health And Disease.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Development; Hypothesis; Immune system; Infection; Schizophrenia

Mesh:

Year:  2015        PMID: 25736181     DOI: 10.1016/j.brainres.2015.02.043

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Shared Immune and Repair Markers During Experimental Toxoplasma Chronic Brain Infection and Schizophrenia.

Authors:  Jakub Tomasik; Tracey L Schultz; Wolfgang Kluge; Robert H Yolken; Sabine Bahn; Vern B Carruthers
Journal:  Schizophr Bull       Date:  2015-09-20       Impact factor: 9.306

2.  IFNγ-Producing γ/δ T Cells Accumulate in the Fetal Brain Following Intrauterine Inflammation.

Authors:  Emma L Lewis; Natalia Tulina; Lauren Anton; Amy G Brown; Paige M Porrett; Michal A Elovitz
Journal:  Front Immunol       Date:  2021-10-04       Impact factor: 8.786

3.  Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives.

Authors:  Evgeny A Ermakov; Mark M Melamud; Valentina N Buneva; Svetlana A Ivanova
Journal:  Front Psychiatry       Date:  2022-04-25       Impact factor: 5.435

4.  Skewing of the antibody repertoire in cerebrospinal fluid B cells from healthy controls and patients with schizophrenia.

Authors:  Sehba Husain-Krautter; Jihui Lee; Duncan Vos; Juan A Gallego; Anil K Malhotra; Thomas L Rothstein
Journal:  Behav Brain Res       Date:  2022-01-07       Impact factor: 3.352

5.  A Role for the Transcription Factor Nk2 Homeobox 1 in Schizophrenia: Convergent Evidence from Animal and Human Studies.

Authors:  Eva A Malt; Katalin Juhasz; Ulrik F Malt; Thomas Naumann
Journal:  Front Behav Neurosci       Date:  2016-03-30       Impact factor: 3.558

6.  Polymorphic Variants of TNFR2 Gene in Schizophrenia and Its Interaction with -308G/A TNF-α Gene Polymorphism.

Authors:  Renata Suchanek-Raif; Paweł Raif; Małgorzata Kowalczyk; Monika Paul-Samojedny; Krzysztof Kucia; Wojciech Merk; Jan Kowalski
Journal:  Mediators Inflamm       Date:  2018-09-04       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.